Comparative study of efficacy of 5% lignocaine patch for post-operative analgesia in cardiac surgical patients: A cross-sectional controlled trial
Trial Snapshot
- Phase
- Not Applicable
- Status
- Not yet recruiting
- Enrollment
- 70
- Locations
- 1
Study Overview
Brief Summary
Post-sternotomy pain remains a significant clinical challenge in cardiac
surgery, often requiring substantial analgesic requirement in the immediate
postoperative period. While opioids are effective analgesics, their adverse
effect profile; including respiratory depression, sedation, gastrointestinal
dysfunction, and risk of long-term dependence; underscores the urgent need
for opioid-sparing strategies.
Topical lidocaine in the form of a 5% transdermal patch offers a non-invasive, low-
risk intervention that provides localized analgesia with minimal systemic
absorption. Although lidocaine patches have demonstrated efficacy in treating
neuropathic and localized pain conditions, their role in the management of acute
post-sternotomy pain remains underexplored.
This study proposes to evaluate the efficacy of the 5% lidocaine patch in reducing
post-sternotomy pain and opioid requirements within the first 24 hours following
cardiac surgery. By addressing a key gap in postoperative pain management, this
research has the potential to inform enhanced recovery pathways, reduce opioid
exposure, and improve patient outcomes in a high-risk population
Study Design
- Study Type
- Observational
Eligibility Criteria
- Ages
- 20.00 Year(s) to 75.00 Year(s) (—)
- Sex
- All
Inclusion Criteria
- •Patients giving consent for procedures 2) Patients in the age group of 20-75 years 3) Patients scheduled to undergo cardiac surgery through a full median sternotomy approach.
Exclusion Criteria
- •Known hypersensitivity or allergic reaction to lignocaine patches.
- •Current use of Class I antiarrhythmic medications, such as lignocaine, tocainide, procainamide, mexiletine, or propafenone.
- •Preoperative use of medications for acute or chronic pain conditions, including non-steroidal anti-inflammatory drugs (NSAIDs), tramadol, opioids, antidepressants, or anticonvulsants.
Investigators
Dr Jaslin Biswajit Acharya
MGM Medical College and Hospital